Publications Angelica Loskog

Publications in DiVA

Publications in PubMed

Selected publications:

Wenthe J, Naseri J, Hellström A-C, Moreno R, Ullenhag G, Alemany R, Lövgren T, Eriksson E, Loskog A. Immune priming using DC and T cell targeting gene therapy sensitizes both treated and distant B16 tumors to PD-L1 checkpoint inhibition. Mol Ther Oncolytics. 2022, 24:429-442.
Labani-Motlagh A, Naseri S, Wenthe J, Eriksson E, Loskog A. Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes. Mol Ther Oncolytics. 2021., 20:508-518.
Irenaeus S, Hellström V, Wenthe J, Krause J, Sundin A, Ahlström H, Tufveson G, Tötterman TH, Loskog A, Ullenhag G. Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors. Cancer Gene Ther. 2021. 28:1188-1197.
Wenthe J, Naseri S, Labani Motlagh A, Enblad G, Wikström KI, Eriksson E, Loskog A, Lövgren T. Boosting CAR T cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunol Immunother. 2021, 70:2851-2865.
Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R, Loskog A. IL-6 signaling blockade during CD40-mediated immune activation favors anti-tumor factors by reducing TGF-beta, collagen type I and PD-L1/PD1. J Immunol. 2019, 202:787-798.
Enblad G, Karlsson H, Gammelgård G, Wenthe J, Lövgren T, Amini R-M, Wikstrom KI, Essand M, Savoldo B, Hallböök H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A. A Phase I/IIa trial using CD19-targeted third generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018, 24:6185-6194.
Ireaneus S, Schiza A, Mangsbo S, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlström H, Tötterman TH, Loskog A, Ullenhag GJ. Local radiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget. 2017, 8:78573-78587.
Eriksson E, Milenova I, Wenthe J, Ståhle M, Leja-Jarblad J, Ullenhag G, Dimberg A, Moreno R, Alemany R, Loskog A. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res. 2017, 23:5846-5857.
Eriksson, E., Wenthe, J., Irenaeus, S., Loskog, A., Ullenhag, G. Gemcitabine reduces MDSCs, Tregs and TGFb-1 while restoring the Teff:Treg ratio in patients with pancreatic cancer. J Transl Med. 2016, 14:282.
Loskog, A., Maleka, A., Mangsbo, S., Svensson, E., Lundberg, C., Nilsson, A., Krause, J., Agnarsdóttir, M., Sundin, A., Ahlström, H., Tötterman, T.H., Ullenhag, G. Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. Br J Cancer. 2016, 114:872-880.